The prevalence and prognostic value of <i>KRAS</i> co‐mutation subtypes in Chinese advanced non‐small cell lung cancer patients

Abstract

Our study revealed that concurrent genomic alterations can further stratify KRAS-mutant lung adenocarcinoma patients into various subgroups with distinctive therapeutic responses and differential survival outcomes. The KPL is a novel and less responsive subtype among KRAS-mutated NSCLC, and further investigation of effective treatment for this subtype is warranted.